Katherine Simone Jacobson, | |
240 E Lake Ave, Watsonville, CA 95076-4718 | |
(831) 728-5808 | |
Not Available |
Full Name | Katherine Simone Jacobson |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 240 E Lake Ave, Watsonville, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1336603778 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC1900X | Psychologist - Counseling | (* (Not Available)) | Secondary |
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Katherine Simone Jacobson, 240 E Lake Ave, Watsonville, CA 95076-4718 Ph: (831) 247-1635 | Katherine Simone Jacobson, 240 E Lake Ave, Watsonville, CA 95076-4718 Ph: (831) 728-5808 |
News Archive
Newer polymer-based formulations of oral rehydration solution given to treat diarrhoea may offer some benefits over older sugar-salt formulations.
Hardy Diagnostics, an FDA licensed and ISO certified biomedical firm, is pleased to announce the release of AloeSafe, a hand sanitizer that contains aloe vera, vitamin E, and lavender oil. Unlike most alcohol based hand sanitizers, AloeSafe is free from potentially harmful ingredients.
Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Antibody to Treponema Pallidum (Anti-TP) in human serum or plasma by a double - antigen sandwich chemiluminescent assay method.
As Congress drafts health care reform legislation, HIV clinicians urge lawmakers to include a public plan option to ensure affordable access to comprehensive care for HIV patients - nearly 30 percent of whom have no insurance. The HIV Medicine Association (HIVMA) believes that a public plan option can help offer everyone the chance to benefit from early and reliable access to lifesaving HIV care and treatment.
The Rare Disease Cures Accelerator-Data and Analytics Platform initiative officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation.
› Verified 3 days ago